Drugmaker Cipla has signed a perpetual license agreement with Novartis Pharma AG (Switzerland) to manufacture and market diabetes drug Galvus and its combination brands from January 1, 2026.
One of the leading brands in the Dipeptidyl Peptidase-4 (DPP4) space, especially in the oral diabetic medication category, Galvus has the potential to contribute significantly to its portfolio with reported sales of ₹268 crore, Cipla said citing the IQVIA (MAT February 2023) number.
The agreement is subject to the satisfaction of certain conditions precedent. In the interim, Cipla will continue to market and distribute Galvus branded products. “This deal is expected to further strengthen Cipla’s position in India as one of the leading players in the diabetes category,” the company said in a stock exchange filing on April 10.
